Summary of Use during Lactation

No information is available on the clinical use of tucatinib during breastfeeding. The manufacturer recommends that breastfeeding be discontinued during tucatinib therapy and for 1 week after the last dose. However, tucatinib is used in combination with trastuzumab and capecitabine. It is recommended that breastfeeding be suspended for 7 months after the use of trastuzumab.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Name

Tucatinib

CAS Registry Number

937263-43-9

Drug Class

Breast Feeding

Lactation

Antineoplastic Agents

Enzyme Inhibitors

Protein Kinase Inhibitors

Signal Transduction Inhibitors

Tyrosine Kinase Inhibitors